Findings from Medarex, Inc. in biotechnology business reported
2009 JUL 8 - (NewsRx.com) -- According to recent research published in the journal Clinical Cancer Research, "This study was undertaken to evaluate the effects of MDX-1401, a nonfucosylated fully human monoclonal antibody that binds to human CD30, and to determine whether it exhibits greater in vitro and in vivo activity than its parental antibody. Assays measuring antibody binding to CD30-expressing cells and Fc gamma RIIIa (CD16) transfectants as well as antibody-dependent cellular cytotoxicity (ADCC) were conducted." "Antitumor activity was determined using a Karpas-299 systemic model. The binding of MDX-1401 to CD30 antigen was identical to fucose-containing parental anti-CD30 antibody (MDX-060). In contrast, MDX-1401 showed increased binding affinity to Fc gamma RIIIa-transfected cells resulting in increased effector function. MDX-1401 greatly improved ADCC activity as evidenced by a decrease in half-maximal effective concentration (EC50) and an increase in maximum cell lysis when compared with MDX-060. Increased ADCC activity was observed among a panel of cell lines, including one with very low CD30 antigen expression in which parental antibody failed to induce any detectable ADCC. MDX-1401 activity with all Fc gamma RIIIa polymorphic variants, including less active Phe/Phe158 and Phe/Val158 effector cells, was shown. Furthermore, MDX-1401 was efficacious in inhibiting tumor growth in CD30(+) lymphoma xenografts," wrote P.M. Cardarelli and colleagues, Medarex, Inc. The researchers concluded: "The low doses of antibody required for ADCC activity irrespective of donor genotype, the ability to mediate ADCC in target cells expressing low levels of CD30, and increased in vivo efficacy support the development of MDX-1401 for treatment of malignant lymphoma." Cardarelli and colleagues published their study in Clinical Cancer Research (In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma. Clinical Cancer Research, 2009;15(10):3376-3383). For additional information, contact P.M. Cardarelli, Medarex, Dept. of Cell Biology & Pharmacology, 1324 Chesapeake Terrace, Sunnyvale, CA 94089, USA. The publisher's contact information for the journal Clinical Cancer Research is: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA. Keywords: United States, Sunnyvale, Anticancer Therapy, Antitumor Activity, Biotechnology, Biotechnology Business, Biotechnology Company, Cancer, Cancer Research, Experimental Design, Hematology, Lymphoma, Medarex Inc., Medical Device, Monoclonal Antibody, Oncology, Treatment, Medarex, Inc. This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright 2009, Immunotherapy Weekly via NewsRx.com.
|
